We are advising Charles River on the agreement

Davis Polk is advising Charles River Laboratories International, Inc. on its cooperation agreement with Elliott Investment Management L.P. under which Elliott has agreed to customary standstill and other provisions. Charles River’s Board of Directors has agreed to appoint four new directors, two of whom are designated by Elliott. Four existing directors will not seek re-election at the Annual Meeting in May 2025. Charles River also announced a strategic review of its business focused on enhancing long-term value for shareholders.

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Its dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

The Davis Polk corporate team includes partners Michael Davis, Shanu Bajaj and Louis Goldberg and associate Andrew R. Board. All members of the Davis Polk team are based in the New York office.

Copy link to share post